Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Antimicrobial Peptides
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : National Institute of Allergy and Infectious Diseases
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : The CLAROMER drug discovery platform generates a family of novel compounds to precisely target infectious pathogens. CLAROMERS can exhibit improved stability and potency relative to natural peptides and are highly scalable to manufacture.
Brand Name : Undisclosed
Molecule Type : Peptide
Upfront Cash : Not Applicable
September 29, 2022
Lead Product(s) : Antimicrobial Peptides
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : National Institute of Allergy and Infectious Diseases
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Ropocamptide
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : DecentraNet
Deal Size : $10.8 million
Deal Type : Financing
Maxwell Biosciences Raises $10.8 Million in Oversubscribed Seed Round
Details : The funding will enable Maxwell to accelerate the development of its innovative platform having LL-37, recruit and retain top talent, pursue clinical trials, and scale up manufacturing capabilities.
Brand Name : LL-37
Molecule Type : Peptide
Upfront Cash : Undisclosed
March 10, 2022
Lead Product(s) : Ropocamptide
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : DecentraNet
Deal Size : $10.8 million
Deal Type : Financing
Lead Product(s) : Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : University of Louisville
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Titled Potent Antiviral Activity against HSV-1 and SARS-CoV-2 by Antimicrobial Peptoids, the research findings demonstrate that several peptoids exhibit potent in vitro antiviral activity against both HSV-1 and SARS-CoV-2.
Brand Name : Undisclosed
Molecule Type : Peptide
Upfront Cash : Not Applicable
April 05, 2021
Lead Product(s) : Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : University of Louisville
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?